PharmaVentures advises Wellmarker Bio on their Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Wellmarker Bio is pleased to sign a clinical collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate a first-in-class treatment with a novel mechanism in
WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration
SEOUL, South Korea, March 3, 2021 /PRNewswire/ Wellmarker Bio(www.wmbio.co) announced that on February 23, 2021 the company received approval from the Australian Therapeutic Goods Administration (TGA) for a Phase I clinical trial using WM-S1-030, a targeted anti-cancer drug for colorectal cancer and progressive cancer.
Under the approval, Wellmarker Bio will seek to recruit a total of 100 advanced cancer patients in multiple centers, including sites in Australia such as the Linear Clinical Center and Monash Hospital, to conduct clinical trials in two stages: Phase Ia (dose escalation) and Phase Ib (dose expansion). We plan to study the drug s safety at various doses in Phase Ia, and in Phase Ib, we will conduct studies for indication expansion as well as combination therapy with chemotherapy, other targeted or cancer immunotherapy drugs along with validation of our pre